Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Matchpoint Therapeutics secures $150 million in Series B financing led by Nextech Invest and Norwest. The funding will advance clinical development of MPT-062 for autoimmune and inflammatory diseases.
Amount Raised
$150 Million
Round Type
Series B
Investors
Description
Matchpoint Therapeutics successfully closed a $150 million Series B financing to support the clinical development of its lead asset, MPT-062. The financing was co-led by Nextech Invest and Norwest, with participation from both new and existing investors. This funding will further progress Matchpoint's product pipeline, which includes innovative therapies for autoimmune and inflammatory diseases. The company looks forward to advancing its programs with the support of its investors.
Fundz sees it the moment Matchpoint Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansMatchpoint Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.